Menu
← Oncology Approval Tracker
FDA DECISION ·
Eribulin mesylate injection (first generic)
eribulin mesylate · Gland Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic of the referenced eribulin injection for metastatic breast cancer after at least two metastatic chemotherapy regimens, or for unresectable or metastatic liposarcoma after an anthracycline-containing regimen.
LAMPGEN ANALYSIS
Why it matters
The first generic approval applies to an IV cytotoxic drug used in two different later-line disease settings.
What research teams should watch
Reconcile chemotherapy history and verify product strength, renal and hepatic function and blood-count thresholds.
PRIMARY RECORDS